Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Not Just COVID, Rapid Expansion Drove CareMax's Ch. 11 No Photo Available

Yun Park

Pressures from rising operational costs, the lingering effects of the COVID pandemic, and inflation have all contributed to CareMax In... (more story)

Meet The Attorneys Directing Film Finances' Ch. 11 Case No Photo Available

Hilary Russ

Global movie production services company Film Finances Inc. is using lawyers from boutique insolvency firm Levene Neale Bender Yoo & G... (more story)

Meet The Attorneys Directing The US Arm Of Stoli's Ch. 11 No Photo Available

Yun Park

A group of Foley & Lardner LLP attorneys is leading the Chapter 11 case for the U.S. arm of vodka giant Stoli Group, which filed for b... (more story)